It has been already reported that COVID-19 infection may predispose patients to thrombotic disease, both in the venous and arterial circulations, due to excessive inflammation, platelet activation, endothelial dysfunction, and stasis. In addition, many patients receiving antithrombotic therapy for thrombotic disease may develop COVID-19, which can have implications for choice, dosing, and laboratory monitoring of antithrombotic therapy. In this very useful paper, just published in the Journal of the American College of Cardiology, Bikdeli et al. review the current understanding of the pathogenesis, epidemiology, management and outcomes of patients with COVID-19 who develop venous or arterial thrombosis, those with preexisting thrombotic disease who develop COVID-19, and those who need prevention or care for thrombotic disease during the COVID-19 pandemic.
by Marialuisa Zedde and Francesco Cavallieri